DR. MARK ROGER OLSEN M.D. NPI 1356382592

NPI Details

DR. Mark Roger Olsen, M.D. is a hematology and oncology internal medicine in Tulsa, OK with 33 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. DR. Mark Roger Olsen, M.D. NPI is 1356382592. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

Education
Medical School: UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE
Graduation Year:1992

The provider's business location address is:

12697 E 51ST ST
TULSA, OK
ZIP 74146-236
Phone: (918) 505-3200
Fax: (918) 505-3253

The NPI 1356382592 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, ferric carboxymaltose, 1 mg (HCPCS:J1439)
• Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml (HCPCS:Q9967)
• Injection, nivolumab, 1 mg (HCPCS:J9299)
• Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram (HCPCS:Q5110)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, oxaliplatin, 0.5 mg (HCPCS:J9263)
• Injection, azacitidine, 1 mg (HCPCS:J9025)
• Injection, fosaprepitant, 1 mg (HCPCS:J1453)
• Injection, daratumumab, 10 mg and hyaluronidase-fihj (HCPCS:J9144)
• Injection, lanreotide, 1 mg (HCPCS:J1930)
• Injection, aprepitant, 1 mg (HCPCS:J0185)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg (HCPCS:Q5118)
• Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units (HCPCS:Q5106)
• Injection, docetaxel, 1 mg (HCPCS:J9171)
• Injection, atezolizumab, 10 mg (HCPCS:J9022)
• Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg (HCPCS:Q5119)
• Injection, granisetron, extended-release, 0.1 mg (HCPCS:J1627)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg (HCPCS:J1568)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, trastuzumab-qyyp, biosimilar, (trazimera), 10 mg (HCPCS:Q5116)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Magnesium level (HCPCS:83735)
• Phosphate level (HCPCS:84100)
• Uric acid level, blood (HCPCS:84550)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml (HCPCS:A9579)
• Injection, bortezomib (velcade), 0.1 mg (HCPCS:J9041)
• Injection, pegfilgrastim-apgf, biosimilar, (nyvepria), 0.5 mg (HCPCS:Q5122)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Injection, leucovorin calcium, per 50 mg (HCPCS:J0640)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Injection, fulvestrant, 25 mg (HCPCS:J9395)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Injection, ondansetron hydrochloride, per 1 mg (HCPCS:J2405)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a (HCPCS:G9678)
• Injection, cisplatin, powder or solution, 10 mg (HCPCS:J9060)
• Ct scan of chest with contrast (HCPCS:71260)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Ct scan of abdomen and pelvis with contrast (HCPCS:74177)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Blood test, thyroid stimulating hormone (tsh) (HCPCS:84443)
• Reticulated (young) platelet measurement (HCPCS:85055)
• Injection, magnesium sulfate, per 500 mg (HCPCS:J3475)
• Iron level (HCPCS:83540)
• Unclassified drugs (HCPCS:J3490)
• Iron binding capacity (HCPCS:83550)
• Ferritin (blood protein) level (HCPCS:82728)
• Psa (prostate specific antigen) measurement, total (HCPCS:84153)
• Blood creatinine level (HCPCS:82565)
• Gammaglobulin (immune system protein) measurement (HCPCS:82784)
• Nuclear medicine study from skull base to mid-thigh with ct scan (HCPCS:78815)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries (HCPCS:A9552)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Urine microalbumin (protein) analysis (HCPCS:82044)
• Beta-2 microglobulin (protein) level (HCPCS:82232)
• Mri scan of brain before and after contrast (HCPCS:70553)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Injection, methylprednisolone sodium succinate, up to 125 mg (HCPCS:J2930)
• Injection, alteplase recombinant, 1 mg (HCPCS:J2997)
• Administration of chemotherapy into vein using push technique (HCPCS:96409)
• X-ray of chest, 2 views (HCPCS:71046)
• New patient office or other outpatient visit, 30-44 minutes (HCPCS:99203)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:M0220)
• Ct scan of soft tissue of neck with contrast (HCPCS:70491)
• Declotting of central venous tube (HCPCS:36593)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:Q0221)

The enumeration date for this NPI number is 6/9/2006 and was last updated on 5/8/2014.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available: